Loading…
LAXIDO ORANGE is a brand name for Sodium. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: For the treatment of chronic constipation. Laxido Orange is also effective in resolving faecal impaction, defined as refractory constipation with faecal loading of the rectum and/or colon. Laxido Orange is indicated in adults, adolescents and the elderly.
Verbatim from this product's MHRA label. Tap a section to expand.
Laxido Orange is for oral use.
Posology Chronic Constipation:
A course of treatment for chronic constipation with Laxido Orange does not normally exceed 2 weeks, although this can be repeated if required. As for all laxatives, prolonged use is not usually recommended. Extended use may be necessary in the care of patients with severe chronic or resistant constipation, secondary to multiple sclerosis or Parkinson's Disease, or induced by regular constipating medication in particular opioids and antimuscarinics.
Adults, adolescents and the elderly: 1-3 sachets daily in divided doses, according to individual response. For extended use, the dose can be adjusted down to 1 or 2 sachets daily.
Children below 12 years old:
Not recommended.
Faecal Impaction:
A course of treatment for faecal impaction with Laxido Orange does not normally exceed 3 days. Adults, adolescents and the elderly: 8 sachets daily, all of which should be consumed within a 6 hour period.
Children below 12 years old:
Not recommended.
Patients with impaired cardiovascular function:
For the treatment of faecal impaction the dose should be divided so that no more than 2 sachets are taken in any one hour.
Patients with renal insufficiency:
No dosage change is necessary for the treatment of constipation or faecal impaction. Method of administration Each sachet should be dissolved in 125 ml water. For use in faecal impaction, 8 sachets may be dissolved in 1 litre of water.
8. g. oedema, shortness of breath, increasing fatigue, dehydration, cardiac failure) Laxido Orange should be stopped immediately and electrolytes measured and any abnormality should be treated appropriately. 5). This medicinal product contains 187mg of sodium per sachet, equivalent to approximately 9% of the WHO recommended maximum daily intake of 2g sodium for an adult.
When used to treat chronic constipation the maximum daily dose of this product is equivalent to approximately 28% of the WHO recommended maximum daily intake for sodium. Laxido Orange is considered high in sodium. This should be particularly taken into account for those on a low salt diet.
5. 5 Interaction with other medicinal products and other forms of interaction Macrogol 3350 raises the solubility of medicinal products that are soluble in alcohol and mainly insoluble in water. 4). g. anti-epileptics. Therefore, other medicines should not be taken orally for one hour before and for one hour after taking Laxido Orange.
Laxido Orange may result in a potential interactive effect if used with starch-based food thickeners. The macrogol ingredient counteracts the thickening effect of starch, effectively liquefying preparations that need to remain thick for people with swallowing problems.
6 Fertility, pregnancy and lactation Pregnancy There are limited amount of data from the use of Laxido Orange in pregnant women. 3). Clinically, no effects during pregnancy are anticipated, since systemic exposure to macrogol 3350 is negligible.
Laxido Orange can be used during pregnancy. Breast-feeding No effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breast-feeding woman to macrogol 3350 is negligible. Laxido Orange can be used during breast-feeding.
Fertility There are no data on the effects of Laxido Orange on fertility in humans. 3). 7 Effects on ability to drive and use machines Laxido Orange has no influence on the ability to drive and use machines. 8 Undesirable effects Reactions related to the gastrointestinal tract occur most commonly.
The fluid content of Laxido Orange when re-constituted with water does not replace regular fluid intake and adequate fluid intake must be maintained. The faecal impaction diagnosis should be confirmed by appropriate physical or radiological examination of the rectum and abdomen.
8. g. oedema, shortness of breath, increasing fatigue, dehydration, cardiac failure) Laxido Orange should be stopped immediately and electrolytes measured and any abnormality should be treated appropriately. 5). This medicinal product contains 187mg of sodium per sachet, equivalent to approximately 9% of the WHO recommended maximum daily intake of 2g sodium for an adult.
When used to treat chronic constipation the maximum daily dose of this product is equivalent to approximately 28% of the WHO recommended maximum daily intake for sodium. Laxido Orange is considered high in sodium. This should be particularly taken into account for those on a low salt diet.
5.
g. ulcerative colitis, Crohn’s disease and toxic megacolon). 1.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Sodium in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
These reactions may occur as a consequence of expansion of the contents of the gastrointestinal tract, and an increase in motility due to the pharmacologic effects of Laxido Orange. Mild diarrhoea usually responds to dose reduction.
The frequency of the adverse effects is not known as it cannot be estimated from the available data. System Organ Class Adverse Event Immune system disorders Allergic reactions, including anaphylaxis, angioedema, dyspnoea, rash, urticaria, and pruritus.
Skin and subcutaneous tissue disorders Erythema Metabolism and nutrition disorders Electrolyte disturbances, particularly hyperkalaemia and hypokalaemia. Nervous system disorders Headache Gastrointestinal disorders Abdominal pain, diarrhoea, vomiting, nausea, dyspepsia, abdominal distension, borborygmi, flatulence, anorectal discomfort.
General disorders and administration site conditions Peripheral oedema Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.